MET基因改变的非小细胞肺癌靶向治疗耐药机制及治疗策略  

Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of Non-small Cell Lung Cancer with MET Alterations

作　　者：李舒展 张新伟 Shuzhan LI;Xinwei ZHANG(Department of Immunology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Tianjin Key Laboratory of Cancer Prevention and Therapy,Tianjin's Clinical Research Center for Cancer,Key Laboratory of Cancer Immunology and Biotherapy,Tianjin 300060,China)

机构地区：[1]天津医科大学肿瘤医院生物治疗科,国家恶性肿瘤临床医学研究中心,天津市“肿瘤防治”重点实验室,天津市恶性肿瘤临床医学研究中心,天津市肿瘤免疫与生物治疗重点实验室,天津300060

出　　处：《中国肺癌杂志》2023年第9期684-691,共8页Chinese Journal of Lung Cancer

基　　金：蕙兰公益基金项目(No.4-1-284)资助。

摘　　要：间质表皮转化因子(mesenchymal to epithelial transition factor,MET)基因改变参与了非小细胞肺癌的增殖、侵袭和转移。MET-酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)已获批用于MET基因改变的非小细胞肺癌,而这些药物的耐药不可避免。MET-TKIs的分子耐药机制错综复杂,尚不完全清楚。本文主要对这些MET-TKIs的潜在耐药机制进行综述,以期为MET基因改变的患者提供合理的治疗思路。Mesenchymal to epithelial transition factor(MET)gene alterations involve in the proliferation,invasion,and metastasis of non-small cell lung cancer.MET-tyrosine kinase inhibitors(TKIs)have been approved to treat non-small cell lung cancer with MET alterations,and resistance to these TKIs is inevitable.Molecular mechanisms of resistance to MET-TKIs are completely unclear.The review focused on potential mechanisms of MET-TKIs resistance and therapeutics strategies to de-lay and prevent resistance.

关 键 词：肺肿瘤 间质表皮转化因子 靶向治疗 耐药 治疗策略 

分 类 号：R734.2[医药卫生—肿瘤]